Agilent Technologies Inc. (NYSE: A), a leader in life sciences, diagnostics, and applied chemical markets, and Visiopharm, a leader in AI-based digital pathology, today announced the signing of a worldwide distribution agreement, enabling...

Visiopharm is very happy to announce that Ralf Huss, M.D, Ph.D. has been appointed as the chairperson of their scientific advisory board. As the new academic leader of the advisory board, he brings a wealth of scientific and industry leadership...

CIO Applications recently sat down with our founder and CEO Michael Grunkin. The technology print magazine focuses on usage of various tech start ups. In the latest issue the spotlight was placed on the marketplace of machine learning...

Courtesy of Dr. Michael Grunkin, CEO, Visiopharm What Is a Hot-Spot and Does It Matter? The importance of hot-spots As discussed in the recent post on managing tumor heterogeneity, it is widely considered best practice to determine the...

Letting Pathologists Harness the Power of AI Hoersholm, Denmark, October 3rd, 2018 – Visiopharm A/S announced today the launch of their AI image analysis platform powered by deep learning. The Oncotopix®/Biotopix™ AI image analysis...

Hørsholm, Denmark, May 5, 2015: Visiopharm, the leader in image analysis for diagnostic digital pathology, announces today the closing of a private round of financing with NorthCap Partners. The investment amount is undisclosed. This...